Author: Lijiao Zeng; Jialu Li; Mingfeng Liao; Rui Hua; Pilai Huang; Mingxia Zhang; Youlong Zhang; Qinlang Shi; Zhaohua Xia; Xinzhong Ning; Dandan Liu; Jiu Mo; Ziyuan Zhou; Zigang Li; Yu Fu; Yuhui Liao; Jing Yuan; Lifei Wang; Qing He; Lei Liu; Kun Qiao
Title: Risk assessment of progression to severe conditions for patients with COVID-19 pneumonia: a single-center retrospective study Document date: 2020_3_30
ID: 8n3q30hy_32
Snippet: SARS-CoV-2 entry host cell through angiotensin-converting enzyme 2 (ACE2) 7 , whose expression can be enhanced by the usage of hypertension medicine such as ACE inhibitors or angiotensin II type-I receptor blockers (ARBs) 8 . Whether such medication is a causal factor for a higher risk of COVID-19 progression is thus under investigation 9 . In our study, we observed that the co-occurred hypertension disorder is significantly related to severe pro.....
Document: SARS-CoV-2 entry host cell through angiotensin-converting enzyme 2 (ACE2) 7 , whose expression can be enhanced by the usage of hypertension medicine such as ACE inhibitors or angiotensin II type-I receptor blockers (ARBs) 8 . Whether such medication is a causal factor for a higher risk of COVID-19 progression is thus under investigation 9 . In our study, we observed that the co-occurred hypertension disorder is significantly related to severe progression, but we did not found association between the medication and severity outcome among hypertension patients. All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Search related documents:
Co phrase search for related documents- entry host and hypertension patient: 1
- entry host and receptor blocker: 1, 2
- entry host and severe progression: 1, 2, 3, 4, 5, 6
- entry host cell and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9
- entry host cell and receptor blocker: 1
- entry host cell and severe progression: 1
- high risk and hypertension disorder: 1, 2
- high risk and hypertension medicine: 1
- high risk and hypertension patient: 1, 2, 3, 4, 5, 6, 7, 8
- high risk and progression high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- high risk and receptor blocker: 1, 2, 3, 4
- high risk and severe progression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- high risk and severity medication: 1
- hypertension patient and receptor blocker: 1, 2
- hypertension patient and severe progression: 1
- progression high risk and severe progression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
- receptor blocker and severe progression: 1
- receptor blocker and severity medication: 1, 2
- receptor blocker and severity medication outcome: 1
Co phrase search for related documents, hyperlinks ordered by date